<DOC>
	<DOCNO>NCT00709215</DOCNO>
	<brief_summary>This two-part , open-label , Phase I/II study subject relapse refractory TdT-positive leukemia standard therapy expect result durable remission .</brief_summary>
	<brief_title>Study Cordycepin Plus Pentostatin Patients With Refractory TdT-Positive Leukemia</brief_title>
	<detailed_description>In first phase Study Objectives : - Define maximally tolerate dose ( MTD ) recommend dose ( RD ) administration cordycepin 1-hour IV infusion , administer 1 hour follow administration IV bolus pentostatin , subject refractory TdT-positive leukemia ; - Determine plasma ADA level prior pentostatin infusion 60 120 minute administration pentostatin ; - Determine single multiple dose pharmacokinetics ( PK ) cordycepin give 1 hour fix dose pentostatin ; - Assess cordycepin pharmacodynamics measurement blast cell apoptosis peripheral blood smear ; - Measure quantitate clinical response refractory TdT-positive leukemia patient follow cordycepin/pentostatin administration . In second phase , Study Objectives assess safety , PK , clinical outcome cordycepin combination pentostatin , RD , 20 subject cohort</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cordycepin</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>TdTpositive leukemia ( ALL , AML , blastic CML ) fail least one standard treatment regimen standard therapy expect result durable remission . Leukemia minimally define least 20 % blast cell present marrow peripheral blood . TdT must express least 20 % blast cell present document either immunologically biochemically ; Age ≥18 year ; Must understand voluntarily sign informed consent ; Adequate nonhematologic organ system function , define : Creatinine ≤1.5 time upper limit normal ( ULN ) and/or creatinine clearance ≥60 mL/min AST and/or ALT ≤2.5 time upper limit normal ( ULN ) Total bilirubin within institutional normal range Normal EKG LVEF &gt; 40 % , measure EKG MUGA scan , radionuclide ventriculogram , echocardiogram Life expectancy &gt; 3 month ; Performance status ( PS ) &gt; 70 % Karnofsky ECOG ≤2 ; Women childbearing potential must negative serum pregnancy test within 7 day start study drug . A woman childbearing potential sexually mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) ; Male female childbearing potential must agree use adequate contraceptive method Failure meet inclusion criterion ; Uncontrolled active infection ; Extramedullary ( CNS ) disease ; Serious concomitant medical illness , active infection , uncontrolled congestive heart failure , uncontrolled diabetes metabolic disorder , psychiatric illness ; Pregnancy lactation ; female child bear potential must use adequate contraceptive method ; Less 3 week since prior chemotherapy , radiation therapy , immunotherapy . However , hydroxyurea permit 24 hour study initiate ; Less 2 month follow bone marrow peripheral blood stem cell transplantation treatment donor lymphocyte infusion ( DLI ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>refractory TdT-positive leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>blastic CML</keyword>
</DOC>